Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area

British Journal of Cancer

Volumn 112, Issue 12, 2015, Pages 1911-1920

  Sideras, K ^a   Bots, S J ^a   Biermann, K ^a   Sprengers, D ^a   Polak, W G ^a   Ijzermans, J N M ^a   De Man, R A ^a   Pan, Q ^a   Sleijfer, S ^b   Bruno, M J ^a   Kwekkeboom, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Annexin A2; Glypican 3; hepatocellular carcinoma; immunohistochemistry; MAGE C1; MAGE C2; tumour antigens; vaccination

Indexed keywords

ALPHA FETOPROTEIN; GLYPICAN 1; LIPOCORTIN 2; MAGE C1 ANTIGEN; MAGE C2 ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MIDKINE; MUCIN 1; NY ESO 1 ANTIGEN; SALL 4 ANTIGEN; SPERM PROTEIN 17; SSX 2 ANTIGEN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR INVASION; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; ENDEMIC DISEASE; EUROPE; GENE EXPRESSION REGULATION; GEOGRAPHY; HEPATITIS B; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LIVER NEOPLASMS; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; ENDEMIC DISEASES; EUROPE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GEOGRAPHY; HEPATITIS B; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; YOUNG ADULT;

EID: 84930852924     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.92     Document Type: Article

References (81)

1. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304: 2154-2160.
2. Brennan DJ, Rexhepaj E, O'Brien SL, McSherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM (2008) Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 14: 2681-2689.
3. Brumm C, Schulze C, Charels K, Morohoshi T, Kloppel G (1989) The significance of alpha-fetoprotein and other tumour markers in differential immunocytochemistry of primary liver tumours. Histopathology 14: 503-513.
4. Cao Y, Karsten U, Otto G, Bannasch P (1999) Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch 434: 503-509.
5. Chau GY, Lee AF, Tsay SH, Ke YR, Kao HL, Wong FH, Tsou AP, Chau YP (2007) Clinicopathological significance of survivin expression in patients with hepatocellular carcinoma. Histopathology 51: 204-218.
6. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337.
7. Chen CH, Chen GJ, Lee HS, Huang GT, Yang PM, Tsai LJ, Chen DS, Sheu JC (2001) Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett 164: 189-195.
8. Deguchi M, Shiraki K, Inoue H, Okano H, Ito T, Yamanaka T, Sugimoto K, Sakai T, Ohmori S, Murata K, Furusaka A, Hisatomi H, Nakano T (2002) Expression of survivin during liver regeneration. Biochem Biophys Res Commun 297: 59-64.
9. dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van Muijen GN, van Kessel AG (2000) Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res 60: 1654-1662.
10. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763.
11. El-Serag HB, Mason AC, Key C (2001) Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33: 62-65.
12. Ferrandez-Izquierdo A, Llombart-Bosch A (1987) Immunohistochemical characterization of 130 cases of primary hepatic carcinomas. Pathol Res Pract 182: 783-791.
13. Filmus J, Capurro M (2013) Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 280: 2471-2476.
14. Frayne J, Hall L (2002) A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm-zona pellucida binding. Reproduction 124: 767-774.
15. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H (2012) Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44: 760-764.
16. Ganjei P, Nadji M, Albores-Saavedra J, Morales AR (1988) Histologic markers in primary and metastatic tumors of the liver. Cancer 62: 1994-1998.
17. Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82: 331-371.
18. Ho DW, Yang ZF, Yi K, Lam CT, Ng MN, Yu WC, Lau J, Wan T, Wang X, Yan Z, Liu H, Zhang Y, Fan ST (2012) Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One 7: e37159.
19. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel CV, Simpson AJ, Old LJ, Hide W (2008) Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A 105: 20422-20427.
20. IARC (2011) Available at http://www-dep.iarc.fr/ (accessed 08.10.14).
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
22. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Busam KJ, Old LJ (2000) Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 83: 493-497.
23. Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M (2005) Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer 35: 53-60.
24. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010a) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422.
25. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010b) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099-1105.
26. Koide N, Hada H, Shinji T, Ujike K, Hirasaki S, Yumoto Y, Hanafusa T, Kadomatsu K, Muramatsu H, Muramatsu T, Tsuji T (1999) Expression of the midkine gene in human hepatocellular carcinomas. Hepatogastroenterology 46: 3189-3196.
27. Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, Hua YP, Totsuka S, Liu SQ, Leong KW, Ohno T (2004) Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10: 1574-1579.
28. Kvistborg P, van Buuren MM, Schumacher TN (2013) Human cancer regression antigens. Curr Opin Immunol 25: 284-290.
29. Lacy HM, Sanderson RD (2001) Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood 98: 2160-2165.
30. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, Godelaine D (2000) Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 86: 835-841.
31. Lang JM, Andrei AC, McNeel DG (2009) Prioritization of cancer antigens: keeping the target in sight. Expert Rev Vaccines 8: 1657-1661.
32. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R (2004) Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases. Mod Pathol 17: 180-188.
33. Lau SK, Prakash S, Geller SA, Alsabeh R (2002) Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 33: 1175-1181.
34. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF (2005) Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 28: 496-504.
35. Li B, He X, Pang X, Zhang H, Chen J, Chen W (2004) Elicitation of both CD4 and CD8 T-cell-mediated specific immune responses to HCA587 protein by autologous dendritic cells. Scand J Immunol 60: 506-513.
36. Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, Ding HG (2011) Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol 17: 4563-4571.
37. Liang J, Ding T, Guo ZW, Yu XJ, Hu YZ, Zheng L, Xu J (2013) Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer 109: 1031-1039.
38. Liu A, Liu D, Zhao S, Zheng J, Cao D, Zhang H (2011) Up regulation of annexin A2 on murine H22 hepatocarcinoma cells induced by cartilage polysaccharide. Cancer Epidemiol 35: 490-496.
39. Liu C, Duan LG, Lu WS, Yan LN, Xiao GQ, Jiang L, Yang J, Yang JY (2014) Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One 9: e103228.
40. Liu Z, Ling Q, Wang J, Xie H, Xu X, Zheng S (2013) Annexin A2 is not a good biomarker for hepatocellular carcinoma in cirrhosis. Oncol Lett 6: 125-129.
41. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Group, S.I.S. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
42. Longerich T, Haller MT, Mogler C, Aulmann S, Lohmann V, Schirmacher P, Brand K (2011) Annexin A2 as a differential diagnostic marker of hepatocellular tumors. Pathol Res Pract 207: 8-14.
43. Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B, Pfreundschuh M (2002) Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2: 11.
44. Ma WJ, Wang HY, Teng LS (2013) Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol 11: 212.
45. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
46. Minervini MI, Demetris AJ, Lee RG, Carr BI, Madariaga J, Nalesnik MA (1997) Utilization of hepatocyte-specific antibody in the immunocytochemical evaluation of liver tumors. Mod Pathol 10: 686-692.
47. Mohammad HS, Kurokohchi K, Yoneyama H, Tokuda M, Morishita A, Jian G, Shi L, Murota M, Tani J, Kato K, Miyoshi H, Deguchi A, Himoto T, Usuki H, Wakabayashi H, Izuishi K, Suzuki Y, Iwama H, Deguchi K, Uchida N, Sabet EA, Arafa UA, Hassan AT, El-Sayed AA, Masaki T (2008) Annexin A2 expression and phosphorylation are up-regulated in hepatocellular carcinoma. Int J Oncol 33: 1157-1163.
48. Monma F, Hozumi Y, Ikematsu S, Kawaguchi M, Kadomatsu K, Suzuki T (2013) Expression of midkine in normal human skin, dermatitis and neoplasms: association with differentiation of keratinocytes. J Dermatol 40: 980-986.
49. Nakamura S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth A, Chen YT, Old LJ, Nakayama E, Shiratori Y (2006) Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 21: 1281-1285.
50. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K (2006) Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19: 804-814.
51. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H (2013) Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology 57: 1469-1483.
52. Peng BG, Liang LJ, He Q, Kuang M, Lia JM, Lu MD, Huang JF (2005a) Tumor vaccine against recurrence of hepatocellular carcinoma. World J Gastroenterol 11: 700-704.
53. Peng JR, Chen HS, Mou DC, Cao J, Cong X, Qin LL, Wei L, Leng XS, Wang Y, Chen WF (2005b) Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219: 223-232.
54. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529-538.
55. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C, Clavien PA, Moch H, Jochum W (2009) Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 124: 352-357.
56. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagohri T, Takahashi S, Gotohda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T (2012) Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 18: 3686-3696.
57. Scharnhorst V, van der Eb AJ, Jochemsen AG (2001) WT1 proteins: functions in growth and differentiation. Gene 273: 141-161.
58. Schultz-Thater E, Piscuoglio S, Iezzi G, Le Magnen C, Zajac P, Carafa V, Terracciano L, Tornillo L, Spagnoli GC (2011) MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int J Cancer 129: 1137-1148.
59. Sera T, Hiasa Y, Mashiba T, Tokumoto Y, Hirooka M, Konishi I, Matsuura B, Michitaka K, Udaka K, Onji M (2008) Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur J Cancer 44: 600-608.
60. Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T (2009) Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 100: 1403-1407.
61. Tsuji M, Kashihara T, Terada N, Mori H (1999) An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, CA19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int 49: 310-317.
62. Vaughan HA, Svobodova S, Macgregor D, Sturrock S, Jungbluth AA, Browning J, Davis ID, Parente P, Chen YT, Stockert St E, Clair F, Old LJ, Cebon J (2004) Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res 10: 8396-8404.
63. Verhoef C, Visser O, de Man RA, de Wilt JH, JN IJ, Janssen-Heijnen ML (2004) Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns. Eur J Cancer 40: 1530-1538.
64. Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, Lu SN, Chen CL (2009) Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 16: 1832-1842.
65. Witjes CD, Karim-Kos HE, Visser O, van den Akker SA, de Vries E, Ijzermans JN, de Man RA, Coebergh JW, Verhoef C (2012) Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival. Eur J Gastroenterol Hepatol 24: 450-457.
66. Wu LQ, Lu Y, Wang XF, Lv ZH, Zhang B, Yang JY (2006) Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma. Life Sci 79: 744-748.
67. Xia QY, Liu S, Li FQ, Huang WB, Shi LN, Zhou XJ (2013) Sperm protein 17, MAGE-C1 and NY-ESO-1 in hepatocellular carcinoma: expression frequency and their correlation with clinical parameters. Int J Clin Exp Pathol 6: 1610-1616.
68. Yakaboski E, Jares A, Ma Y (2014) Stem cell gene SALL4 in aggressive hepatocellular carcinoma: a cancer stem cell-specific target? Hepatology 60: 419-421.
69. Yan B, Wei JJ, Qian YM, Zhao XL, Zhang WW, Xu AM, Zhang SH (2011) Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann Diagn Pathol 15: 162-169.
70. Yee DS, Narula N, Ramzy I, Boker J, Ahlering TE, Skarecky DW, Ornstein DK (2007) Reduced annexin II protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Arch Pathol Lab Med 131: 902-908.
71. Yong KJ, Chai L, Tenen DG (2013a) Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 369: 1171-1172.
72. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, Ravikumar S, Srivastava S, Tian X, Poon RT, Fan ST, Luk JM, Dan YY, Salto-Tellez M, Chai L, Tenen DG (2013b) Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 368: 2266-2276.
73. Yorita K, Takahashi N, Takai H, Kato A, Suzuki M, Ishiguro T, Ohtomo T, Nagaike K, Kondo K, Chijiiwa K, Kataoka H (2011) Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Liver Int 31: 120-131.
74. Yu GR, Kim SH, Park SH, Cui XD, Xu DY, Yu HC, Cho BH, Yeom YI, Kim SS, Kim SB, Chu IS, Kim DG (2007) Identification of molecular markers for the oncogenic differentiation of hepatocellular carcinoma. Exp Mol Med 39: 641-652.
75. Zeng SS, Yamashita T, Kondo M, Nio K, Hayashi T, Hara Y, Nomura Y, Yoshida M, Hayashi T, Oishi N, Ikeda H, Honda M, Kaneko S (2014) The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma. J Hepatol 60: 127-134.
76. Zhang X, Liu S, Guo C, Zong J, Sun MZ (2012) The association of annexin A2 and cancers. Clin Transl Oncol 14: 634-640.
77. Zhao P, Zhang W, Tang J, Ma XK, Dai JY, Li Y, Jiang JL, Zhang SH, Chen ZN (2010) Annexin II promotes invasion and migration of human hepatocellular carcinoma cells in vitro via its interaction with HAb18G/CD147. Cancer Sci 101: 387-395.
78. Zheng L, Jaffee EM (2012) Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. Oncoimmunology 1: 112-114.
79. Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, Loffredo CA, Forgues M, Huang H, Xing XJ, Ren N, Dong QZ, Zhou HJ, Ren ZG, Zhao NQ, Wang XW, Tang ZY, Qin LX, Ye QH (2013) Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res 19: 3944-3954.
80. Zhuang R, Zhu Y, Fang L, Liu XS, Tian Y, Chen LH, Ouyang WM, Xu XG, Jian JL, Gure AO, Fortunato S, Ritter G, Old LJ, Simpson AJ, Chen YT, Jin B, Jungbluth AA (2006) Generation of monoclonal antibodies to cancer/testis (CT) antigen CT10/MAGE-C2. Cancer Immun 6: 7.
81. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.